COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
Multiple Sclerosis and Related Disorders(2021)
Abstract
•We report on 272 cladribine tablets (CladT)-treated patients who acquired COVID-19.•Of the total evaluable cohort, 40 (15%) experienced serious COVID-19.•Median onset of COVID-19 from recent preceding CladT treatment course was 162 days.•51% of patients were recovered/recovering at time of analysis (to 15 January 2021).
MoreTranslated text
Key words
Cladribine tablets,COVID-19,Multiple sclerosis
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined